Key clinical point: The probiotic Bifidobacterium breve Bif195 could reduce the risk of aspirin-related small intestinal enteropathy.
Major finding: Participants given Bifidobacterium breve Bif195 had a significantly lower area under the curve for Lewis score than did those in the control group (3,040 vs. 4,351 arbitrary units; P = .0376).
Study details: A prospective, randomized, double-blind, placebo-controlled trial that included 75 healthy volunteers.
Disclosures: The study was funded by Chr. Hansen A/S. One author reported additional support from the Science Foundation Ireland.
Mortensen B et al. Gastroenterology. 2019 May 13. doi: 10.1053/j.gastro.2019.05.008.